HRP20181506T1 - Derivati heteroaril-butanske kiseline kao inhibitori lta4h - Google Patents

Derivati heteroaril-butanske kiseline kao inhibitori lta4h

Info

Publication number
HRP20181506T1
HRP20181506T1 HRP20181506TT HRP20181506T HRP20181506T1 HR P20181506 T1 HRP20181506 T1 HR P20181506T1 HR P20181506T T HRP20181506T T HR P20181506TT HR P20181506 T HRP20181506 T HR P20181506T HR P20181506 T1 HRP20181506 T1 HR P20181506T1
Authority
HR
Croatia
Prior art keywords
lta4h
heteroaryl
inhibitors
acid derivatives
butanic acid
Prior art date
Application number
HRP20181506TT
Other languages
English (en)
Croatian (hr)
Inventor
Birgit Bollbuck
Christian Markert
Wolfgang Miltz
Till Roehn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20181506T1 publication Critical patent/HRP20181506T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20181506TT 2013-12-20 2014-12-18 Derivati heteroaril-butanske kiseline kao inhibitori lta4h HRP20181506T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13199138 2013-12-20
EP14181155 2014-08-15
EP14833234.9A EP3083564B1 (en) 2013-12-20 2014-12-18 Heteroaryl butanoic acid derivatives as lta4h inhibitors
PCT/IB2014/067086 WO2015092740A1 (en) 2013-12-20 2014-12-18 Heteroaryl butanoic acid derivatives as lta4h inhibitors

Publications (1)

Publication Number Publication Date
HRP20181506T1 true HRP20181506T1 (hr) 2018-11-02

Family

ID=52434892

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181506TT HRP20181506T1 (hr) 2013-12-20 2014-12-18 Derivati heteroaril-butanske kiseline kao inhibitori lta4h

Country Status (38)

Country Link
US (4) US9981926B2 (enExample)
EP (1) EP3083564B1 (enExample)
JP (1) JP6500024B2 (enExample)
KR (2) KR102368958B1 (enExample)
CN (1) CN105829286B (enExample)
AP (1) AP2016009301A0 (enExample)
AU (1) AU2014369180B2 (enExample)
BR (1) BR112016011170B1 (enExample)
CA (1) CA2927564C (enExample)
CL (1) CL2016001255A1 (enExample)
CR (1) CR20160279A (enExample)
CU (1) CU24360B1 (enExample)
CY (1) CY1120715T1 (enExample)
DK (1) DK3083564T3 (enExample)
EA (1) EA034436B1 (enExample)
EC (1) ECSP16062173A (enExample)
ES (1) ES2690790T3 (enExample)
GT (1) GT201600132A (enExample)
HR (1) HRP20181506T1 (enExample)
HU (1) HUE039615T2 (enExample)
IL (1) IL245011B (enExample)
LT (1) LT3083564T (enExample)
MX (1) MX2016008247A (enExample)
MY (1) MY180165A (enExample)
NZ (1) NZ719169A (enExample)
PE (1) PE20160899A1 (enExample)
PH (1) PH12016500814B1 (enExample)
PL (1) PL3083564T3 (enExample)
PT (1) PT3083564T (enExample)
RS (1) RS57642B1 (enExample)
SG (1) SG11201602787YA (enExample)
SI (1) SI3083564T1 (enExample)
SV (1) SV2016005230A (enExample)
TN (1) TN2016000127A1 (enExample)
UA (1) UA117498C2 (enExample)
UY (1) UY36178A (enExample)
WO (1) WO2015092740A1 (enExample)
ZA (1) ZA201602445B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201602787YA (en) 2013-12-20 2016-07-28 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
AU2019271122A1 (en) 2018-05-15 2020-11-12 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
MX2021000925A (es) 2018-07-25 2021-03-31 Novartis Ag Inhibidores de inflamasoma nlrp3.
CN112513026B (zh) * 2018-07-31 2025-02-25 诺华股份有限公司 Lta4h抑制剂的晶型
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
US20220117949A1 (en) * 2019-01-11 2022-04-21 Novartis Ag Lta4h inhibitors for the treatment of hidradenitis suppurativa
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
IL299091A (en) 2020-08-14 2023-02-01 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and their medicinal uses
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549831A1 (fr) 1983-07-27 1985-02-01 Rhone Poulenc Agrochimie Nouveaux derives d'acides aryloxybenzoiques, et leur utilisation comme herbicides
US4708965A (en) 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
EP0260817B1 (en) 1986-08-21 1991-05-15 Pfizer Inc. Quinazolinediones and pyridopyrimidinediones
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5750532A (en) 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
CA1315279C (en) 1987-01-12 1993-03-30 Nancy Grace Bollinger Anti-inflammatory agents
US4820723A (en) * 1987-08-14 1989-04-11 Eli Lilly And Company Disubstituted tetrazole leukotriene antagonists and methods for their use thereas
US5055481A (en) 1989-03-24 1991-10-08 Wakamoto Pharmaceutical Co., Ltd. Tetrazole derivatives and aldose reductase inhibition therewith
WO1991000858A1 (en) 1989-07-07 1991-01-24 Schering Corporation Pharmaceutically active compounds
EP0825989A1 (en) * 1995-05-19 1998-03-04 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US6037345A (en) 1998-01-13 2000-03-14 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives
JP4854855B2 (ja) 1999-02-11 2012-01-18 エミスフェアー・テクノロジーズ・インク オキサジアゾール化合物及び活性剤をデリバリーするための組成物
EP1157101B1 (en) 1999-02-26 2006-10-04 Jesper Z. Haeggström Drug design based on the three-dimensional structure of lta4 hydrolase
RU2001129155A (ru) 1999-03-26 2003-08-10 Еро-Сельтик С.А. (Lu) Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале
AU2001261832A1 (en) 2000-05-09 2001-11-20 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
US20020183306A1 (en) 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
JP2006501179A (ja) * 2002-06-27 2006-01-12 ニトロメッド インコーポレーティッド シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
AU2003301305A1 (en) 2002-10-17 2004-05-04 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
WO2005027886A2 (en) 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
GB0230025D0 (en) * 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20070105104A1 (en) 2003-05-06 2007-05-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
GB0410103D0 (en) 2004-05-06 2004-06-09 Biolipox Ab New method
WO2006008142A1 (en) 2004-07-20 2006-01-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and therapy of psoriasis vulgaris
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0524786D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US7728032B2 (en) 2006-08-04 2010-06-01 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation
US7989480B2 (en) 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
TW200906396A (en) 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
EP1958631A1 (en) 2007-02-14 2008-08-20 AEterna Zentaris GmbH Novel triazole derivatives as ligands of G-protein coupled receptors
WO2008117970A1 (en) 2007-03-23 2008-10-02 Korea University Industrial & Academic Collaboration Foundation Use of inhibitors of leukotriene b4 receptor blt2 for treating human cancers
JP2013532734A (ja) 2010-08-04 2013-08-19 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾患を治療するための組成物及び方法
WO2013119946A1 (en) * 2012-02-08 2013-08-15 Of Virginia Patent Foundation University Long chain base sphingosine kinase inhibitors
EP2827849A4 (en) 2012-03-23 2015-11-18 Univ Leland Stanford Junior TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN
EP2885285B1 (en) 2012-07-17 2016-10-19 Boehringer Ingelheim International GmbH Pyrazole drivatives which inhibit leukotriene production
WO2014165090A1 (en) 2013-03-13 2014-10-09 The Broad Institute, Inc. Compounds for the treatment of tuberculosis
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
SG11201602787YA (en) 2013-12-20 2016-07-28 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors

Also Published As

Publication number Publication date
EA201691293A1 (ru) 2016-10-31
PT3083564T (pt) 2018-11-07
CA2927564A1 (en) 2015-06-25
KR20220028175A (ko) 2022-03-08
SG11201602787YA (en) 2016-07-28
US20220411385A1 (en) 2022-12-29
TN2016000127A1 (en) 2017-10-06
MY180165A (en) 2020-11-24
BR112016011170B1 (pt) 2023-01-10
SI3083564T1 (sl) 2018-10-30
RS57642B1 (sr) 2018-11-30
US9981926B2 (en) 2018-05-29
CN105829286B (zh) 2019-05-31
EP3083564A1 (en) 2016-10-26
CY1120715T1 (el) 2019-12-11
KR20160101065A (ko) 2016-08-24
AU2014369180B2 (en) 2016-11-17
SV2016005230A (es) 2016-11-21
UY36178A (es) 2017-01-31
HUE039615T2 (hu) 2019-01-28
JP6500024B2 (ja) 2019-04-10
CU24360B1 (es) 2018-10-04
PH12016500814B1 (en) 2019-05-08
KR102368958B1 (ko) 2022-02-28
GT201600132A (es) 2018-11-27
AP2016009301A0 (en) 2016-06-30
US20170015637A1 (en) 2017-01-19
MX2016008247A (es) 2016-10-21
BR112016011170A8 (pt) 2020-04-28
PE20160899A1 (es) 2016-09-03
US11453651B2 (en) 2022-09-27
PH12016500814A1 (en) 2016-06-13
IL245011A0 (en) 2016-05-31
LT3083564T (lt) 2018-09-25
WO2015092740A1 (en) 2015-06-25
PL3083564T3 (pl) 2018-12-31
ES2690790T3 (es) 2018-11-22
NZ719169A (en) 2018-08-31
US20210340112A1 (en) 2021-11-04
US20180170887A1 (en) 2018-06-21
JP2017505293A (ja) 2017-02-16
CL2016001255A1 (es) 2016-11-18
CA2927564C (en) 2022-09-20
ZA201602445B (en) 2019-01-30
IL245011B (en) 2019-07-31
EP3083564B1 (en) 2018-07-11
US12378206B2 (en) 2025-08-05
CR20160279A (es) 2016-08-31
UA117498C2 (uk) 2018-08-10
CN105829286A (zh) 2016-08-03
DK3083564T3 (en) 2018-10-22
ECSP16062173A (es) 2018-05-31
EA034436B1 (ru) 2020-02-07
KR102423640B1 (ko) 2022-07-22

Similar Documents

Publication Publication Date Title
HRP20181506T1 (hr) Derivati heteroaril-butanske kiseline kao inhibitori lta4h
SI3786162T1 (sl) Bipirazolni derivati kot zaviralci JAK
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
LT3290407T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
HRP20180900T1 (hr) Heterociklički amidi kao inhibitori kinaza
DK2875743T3 (da) Kittel
AR094664A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
SMT201700363T1 (it) Inibitori di bromodominio cristallini
LT2968221T (lt) S-ketamino hidrochlorido farmacinė kompozicija
HRP20180684T1 (hr) Kombinacija lijekova
HUE053047T2 (hu) MDM2 inhibitor kristályos formája
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
HRP20181908T1 (hr) Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze
PT2964616T (pt) Inibidores da neprilisina
HUE053112T2 (hu) PDE 4 inhibitor kristályos formája
HUE046470T2 (hu) Izokromén származékok mint foszfoinozitid-3-kinázok inhibitorai
EP3632467C0 (en) COMPLEMENT FACTOR H INHIBITORS
DK2952513T3 (da) Azolbenzenderivat
EP2945942A4 (en) Voriconazole IMMUNOASSAY
HRP20181197T1 (hr) Derivati n-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamida kao inhibitori glukozilceramid sintaze
HRP20180632T1 (hr) Supstituirani derivati piridina korisni kao inhibitori c-fms kinaze
IL239971A0 (en) Isometheptene isomer
HRP20182110T1 (hr) Sastav spojeva tiakumicina
EP3009444A4 (en) ALPHA-oxoacyl-Amino-caprolactam derivative